203 related articles for article (PubMed ID: 22736772)
1. Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B.
Neary NM; El-Maouche D; Hopkins R; Libutti SK; Moses AM; Weinstein LS
J Clin Endocrinol Metab; 2012 Sep; 97(9):3025-30. PubMed ID: 22736772
[TBL] [Abstract][Full Text] [Related]
2. Progression of PTH Resistance in Autosomal Dominant Pseudohypoparathyroidism Type Ib Due to Maternal STX16 Deletions.
Kiuchi Z; Reyes M; Hanna P; Sharma A; DeClue T; Olney RC; Tebben P; Jüppner H
J Clin Endocrinol Metab; 2022 Jan; 107(2):e681-e687. PubMed ID: 34477200
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet as adjunctive therapy in pseudohypoparathyroidism type 1b.
Srivastava T; Krudys J; Mardis NJ; Sebestyen-VanSickle J; Alon US
Pediatr Nephrol; 2016 May; 31(5):795-800. PubMed ID: 26628282
[TBL] [Abstract][Full Text] [Related]
4. Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a.
Itoh M; Okajima M; Kittaka Y; Yachie A; Wada T; Saikawa Y
Bone Rep; 2022 Jun; 16():101569. PubMed ID: 35497370
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Pre-operative Cinacalcet Administration Reduces Immediate Post-operative Hypocalcemia Following Total Parathyroidectomy in Severe Renal Hyperparathyroidism.
Fung MM; Tam DS; Lui DT; Lang BH
World J Surg; 2023 Aug; 47(8):1986-1994. PubMed ID: 37140608
[TBL] [Abstract][Full Text] [Related]
7. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
8. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
9. Multiple brown tumors: a bone complication due to long-term untreated pseudohypoparathyroidism.
Gonnelli S; Briot K; Cormier C; Teboul S; Roux C; Koumakis E
Osteoporos Int; 2024 Jan; 35(1):195-199. PubMed ID: 37644196
[TBL] [Abstract][Full Text] [Related]
10. Pseudohypoparathyroidism and idiopathic hypoparathyroidism: relationship between serum calcium and parathyroid hormone levels and urinary cyclic adenosine-3',5'-monophosphate response to parathyroid extract.
Werder EA; Fischer JA; Illig R; Kind HP; Bernasconi S; Fanconi A; Prader A
J Clin Endocrinol Metab; 1978 Jun; 46(6):872-9. PubMed ID: 233700
[TBL] [Abstract][Full Text] [Related]
11. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism--the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis.
Parfitt AM
Metabolism; 1976 Oct; 25(10):1157-88. PubMed ID: 787723
[TBL] [Abstract][Full Text] [Related]
12. Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib.
Tollin SR; Perlmutter S; Aloia JF
J Bone Miner Res; 2000 Jul; 15(7):1412-6. PubMed ID: 10893692
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E
Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
[TBL] [Abstract][Full Text] [Related]
15. 1,25-Dihydroxycholecalciferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism.
Drezner MK; Neelon FA; Haussler M; McPherson HT; Lebovitz HE
J Clin Endocrinol Metab; 1976 Apr; 42(4):621-8. PubMed ID: 1083395
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
17. Current advances in the therapy of secondary hyperparathyroidism and osteitis fibrosa.
Llach F; Nikakhtar B
Miner Electrolyte Metab; 1991; 17(4):250-5. PubMed ID: 1813787
[TBL] [Abstract][Full Text] [Related]
18. Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol.
Lorenz K; Ukkat J; Sekulla C; Gimm O; Brauckhoff M; Dralle H
World J Surg; 2006 May; 30(5):743-51. PubMed ID: 16680589
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of a diurnal variation in serum parathyroid hormone in primary and secondary hyperparathyroidism.
Sinha TK; Miller S; Feming J; Khairi R; Edmondson J; Johnston CC; Bell NH
J Clin Endocrinol Metab; 1975 Dec; 41(06):1009-13. PubMed ID: 1239461
[TBL] [Abstract][Full Text] [Related]
20. Osteitis fibrosa cystica with renal parathyroid hormone resistance: a review of pseudohypoparathyroidism with insight into calcium homeostasis.
Eubanks PJ; Stabile BE
Arch Surg; 1998 Jun; 133(6):673-6. PubMed ID: 9637471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
